Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
From Evidence to Access: Aligning Strategy with Payer Decision-Making
Effective market access requires more than demonstrating clinical value. Explore how payer decisions shape coverage, evidence needs and engagement throughout the product lifecycle.
-
Medicare Drug Price Negotiation Program: The Physician Office Outlook for Part B Drugs
Magnolia Market Access examines how Medicare Part B drug administrations have shifted between physician offices and hospital outpatient departments, and what those trends could mean as more drugs become subject to Medicare price negotiation.
-
Four Cents per Beneficiary a Month: Breaking Down GLOBE’s Medicare Part B Premium Savings
CMS significantly reduced its projected savings for the GLOBE Model in the final rule. While the model is expected to generate $440 million in Medicare Part B savings, the estimated impact on beneficiary premiums is only about four cents per month.
-
2026 Health Policy Update: Implications for Biopharma Heading Into 2027
Biopharma companies are facing overlapping policy changes across pricing, reimbursement, 340B, PBM reform, and Medicare drug negotiation. Explore the key developments shaping product, portfolio, and market access decisions heading into 2027.
-
FDA’s 2026 Draft Guidance on Payer Communications
FDA’s 2026 draft guidance updates the framework for manufacturer communications with payors, formulary committees, and similar entities. The revised guidance clarifies expectations for drugs and devices, health care economic information, unapproved product communications, and follow-up when previously shared information becomes materially outdated.
-
AI in Market Access: The Real Opportunity Is Better Payer Alignment
AI in market access can help biopharma teams apply payer intelligence earlier and more consistently across evidence, pricing, launch, and access strategy.
-
The U.S. Biopharmaceutical Innovation Ecosystem at Risk: The 20-Year Threat to U.S. Innovation and Cures
A 20-year analysis of how research funding instability, FDA capacity challenges, and pricing policy pressures may affect future medicines, patient access, and U.S. biotech innovation.
-
Better Evidence Starts With the Right Claims Data Source
ISPOR 2026 research from Magnolia Market Access highlights why the right claims data source depends on the evidence question, outcome, and decision it needs to support.
-
Designing Evidence That Supports Access Decisions
Real-world evidence can help reduce uncertainty in access decisions by addressing questions clinical trials may not fully answer, including long-term outcomes, real-world utilization, and system-level impact.
-
Access Is a Design Decision: Why Commercial Performance Is Now Determined by Access, Not Approval
Access is now shaping commercial performance. Learn how policy, payer dynamics, and evidence are redefining access strategy and what it requires from organizations today.
-
Patient Support Services Modeling, Made Actionable
A data-driven approach to patient support services modeling that helps manufacturers forecast demand, evaluate program design, and manage affordability, access, and cost with confidence.
-
Where Ecosystem Mapping Becomes Strategy
Market access ecosystem mapping helps biopharma teams move from identifying stakeholders to understanding how influence operates across the access landscape, enabling more coordinated engagement, stronger alignment, and more informed decision-making.